Cyclerion Therapeutics Inc (CYCN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cyclerion Therapeutics Inc stock (CYCN) is currently trading at $1.64. Cyclerion Therapeutics Inc PS ratio (Price-to-Sales) is 2.12. Analyst consensus price target for CYCN is $8.00. WallStSmart rates CYCN as Sell.
- CYCN PE ratio analysis and historical PE chart
- CYCN PS ratio (Price-to-Sales) history and trend
- CYCN intrinsic value — DCF, Graham Number, EPV models
- CYCN stock price prediction 2025 2026 2027 2028 2029 2030
- CYCN fair value vs current price
- CYCN insider transactions and insider buying
- Is CYCN undervalued or overvalued?
- Cyclerion Therapeutics Inc financial analysis — revenue, earnings, cash flow
- CYCN Piotroski F-Score and Altman Z-Score
- CYCN analyst price target and Smart Rating
Cyclerion Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Cyclerion Therapeutics Inc (CYCN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Cyclerion Therapeutics Inc (CYCN) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 351.00% year-over-year
Supporting Valuation Data
Cyclerion Therapeutics Inc (CYCN) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very low institutional interest at 7.08%
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.12x sales
Cyclerion Therapeutics Inc (CYCN) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (0.63) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 351.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (2.12) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -24.80%, Operating Margin at -115.00%, Profit Margin at -77.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -24.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 351.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CYCN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CYCN's Price-to-Sales ratio of 2.12x trades at a deep discount to its historical average of 12.27x (25th percentile). The current valuation is 96% below its historical high of 52.8x set in Jun 2023, and 248% above its historical low of 0.61x in Jun 2022. Over the past 12 months, the PS ratio has compressed from ~4.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cyclerion Therapeutics Inc (CYCN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Cyclerion Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 3M with 351% growth year-over-year. The company is currently unprofitable, posting a -77.0% profit margin.
Key Findings
Revenue growing at 351% YoY, reaching 3M. This pace significantly outperforms most BIOTECHNOLOGY peers.
The company is unprofitable with a -77.0% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -264,000, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Cyclerion Therapeutics Inc maintain 351%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Cyclerion Therapeutics Inc.
Bottom Line
Cyclerion Therapeutics Inc is a high-conviction growth story with revenue accelerating at 351% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -77.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Cyclerion Therapeutics Inc(CYCN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.